Ensysce Biosciences, Inc.
ENSC Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.45
KIRA · Stoqly’s AI analyst, in plain words
- Ensysce Biosciences, Inc. had $5.1M of revenue in fiscal 2025, down 2.8% on the year before. Over five years, revenue changed +5.2% a year on average.
- Its operating margin was −202.1%, down 72.9 pts: of every 100 in sales, about −202 is left after running the business.
- Ensysce Biosciences, Inc. lost $10.2M in fiscal 2025.
- Free cash flow was −$7.9M in fiscal 2025, −156.5% of revenue.
Market cap
$5.9M
P/E
—
Revenue
$5.1M
Net income
−$10.2M
Free cash flow
−$7.9M
Operating margin
−202.1%
Ensysce Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−2.8%
No. Sales fell 2.8% last year.
Does it make a profit?
−200.8%
No. It lost money last year.
Does profit turn into cash?
−156.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ensysce Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Ensysce Biosciences, Inc.
- CIK
- 0001716947
Ensysce Biosciences, Inc. · ENSC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.5M | $2.5M | $2.2M | $5.2M | $5.1M |
| Revenue growth | −10.2% | −28.5% | −11.6% | 133.6% | −2.8% |
| Operating margin | −562.7% | −959.9% | −480.5% | −129.2% | −202.1% |
| Net income | −$29.1M | −$24.2M | −$10.6M | −$8.0M | −$10.2M |
| Net margin | −825.4% | −959.3% | −476.4% | −153.3% | −200.8% |
| Diluted EPS | −$1.48 | −$139.42 | −$70.40 | −$11.45 | −$3.98 |
| Cash | |||||
| Cash from operations | −$8.2M | −$17.9M | −$10.8M | −$7.5M | −$7.8M |
| Capital expenditure | — | — | — | — | $0.1M |
| Free cash flow | — | — | — | — | −$7.9M |
| FCF margin | — | — | — | — | −156.5% |
| Share count change | 22.2% | −99.1% | −16.1% | 362.4% | 266.5% |
| Debt and strength | |||||
| Cash and short-term investments | $12.3M | $3.1M | $1.1M | $3.5M | $4.3M |
| Shareholders' equity | −$7.9M | −$3.7M | −$0.3M | $3.7M | $3.2M |
| Current ratio | 1.0x | 0.6x | 0.7x | 2.4x | 1.6x |
| Interest coverage | −15.3x | −221.2x | −30.3x | −5.2x | −544.7x |
| Returns and quality | |||||
| Return on equity | — | — | — | −471.8% | −294.0% |
| Return on tangible equity | — | — | — | −215.4% | −316.6% |
| Piotroski F-score | 2 | 3 | 4 | 4 | 2 |
| Altman Z'' | −25.8 | −94.1 | −175.6 | −78.1 | −67.3 |
Insiders bought, 12 months
$0.4M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ensysce Biosciences, Inc. · ENSC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.45 a share, the company is worth $5.9M.
Source: SEC EDGAR XBRL filings (CIK 0001716947). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.